Design Therapeutics (DSGN) Competitors

Design Therapeutics (NASDAQ:DSGN) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.

Is DSGN or PAHC more profitable?

Phibro Animal Health has a net margin of 1.75% compared to Design Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-18.01%	-17.38%
Phibro Animal Health	1.75%	25.35%	6.21%

Do insiders and institutionals have more ownership in DSGN or PAHC?

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor DSGN or PAHC?

Phibro Animal Health received 306 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 59.96% of users gave Phibro Animal Health an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.

Company	Underperform	Outperform
Design Therapeutics	Outperform Votes 10 33.33%	Underperform Votes 20 66.67%
Phibro Animal Health	Outperform Votes 316 59.96%	Underperform Votes 211 40.04%

Which has preferable earnings and valuation, DSGN or PAHC?

Phibro Animal Health has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$66.86M	-$0.88	-3.86
Phibro Animal Health	$1.11B	0.70	$2.42M	$0.48	39.98

Which has more risk & volatility, DSGN or PAHC?

Design Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Does the media prefer DSGN or PAHC?

In the previous week, Phibro Animal Health had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 0 mentions for Design Therapeutics. Phibro Animal Health's average media sentiment score of 1.57 beat Design Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Neutral
Phibro Animal Health	Very Positive

Do analysts rate DSGN or PAHC?

Design Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 135.29%. Phibro Animal Health has a consensus price target of $21.00, suggesting a potential upside of 9.43%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Phibro Animal Health beats Design Therapeutics on 13 of the 17 factors compared between the two stocks.